Latest in News & Research
Response-Adapted Treatment De-escalation Cost-Effective in Melanoma
Response-adapted de-escalation of immunotherapy yielded incremental net monetary benefit of $28,849 versus standard of care
By Dermsquared Editorial Team | | October 19, 2022
Side Effect and Life-Long Use Concerns Are Barriers to Minoxidil Use
Main reason for stopping minoxidil is lack of effectiveness
By Dermsquared Editorial Team | | October 19, 2022
Comorbidity Burden Higher in Generalized Pustular Psoriasis
Most prevalent conditions in GPP were hypertension, psoriatic arthritis, type 2 diabetes, hyperlipidemia
By Physician’s Briefing Staff | | October 19, 2022
Online Symptom Checkers Often Not Accurate for ID'ing Skin Rashes
Even when correct in diagnosis, broad differentials and low specificity of results contribute to diagnostic uncertainty
By Physician’s Briefing Staff | | October 18, 2022
COVID-19 Mainly Mild, Moderate in Eczema Patients Receiving Tralokinumab
76 of 77 patients with COVID-19 were unvaccinated; no new safety signals reported after COVID-19 vaccination
By Dermsquared Editorial Team | | October 12, 2022
Instruments ID'd for Measuring Eczema Control, Itch Intensity
Consensus reached for Recap of Atopic Eczema and Atopic Dermatitis Control Tool for measuring eczema control
By Dermsquared Editorial Team | | October 12, 2022
Lenabasum Studied for Refractory Cutaneous Dermatomyositis
Results of phase 2 study suggest clinical benefit and favorable safety profile, warranting further study of lenabasum for DM
By Physician's Briefing Staff | | October 11, 2022
Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma
Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition
By Physician’s Briefing Staff | | October 06, 2022
High Sunburn Frequency Through Life Linked to Melanoma, cSCC Risk
Stable high and high-to-low trajectories had increased risks compared with stable low trajectory
By Dermsquared Editorial Team | | October 05, 2022
More Eczema Patients Achieve Itch-Free State With Ruxolitinib
Difference in itch numerical rating scale 0/1 was significant on day 2 and persisted through week 8
By Dermsquared Editorial Team | | October 05, 2022
IV Immune Globulin Bests Placebo for Dermatomyositis
More adults receiving IVIG versus placebo had Total Improvement Score of at least 20 at 16 weeks
By Physician's Briefing Staff | | October 05, 2022
Apremilast May Offer Cardiometabolic Benefit in Psoriasis Patients
5 to 6 percent decrease seen in subcutaneous and visceral adiposity at week 16 of treatment, which was maintained at 52 weeks
By Physician’s Briefing Staff | | October 04, 2022
FDA Approves Dupixent for Prurigo Nodularis
This priority review-based approval makes Dupixent the first treatment for the inflammatory skin condition
By Physician’s Briefing Staff | | September 30, 2022
Is Long-Term Tapinarof Cream Safe, Effective for Psoriasis?
For up to one year, 40.9 percent of patients achieved complete disease clearance with a four-month remittive effect; no new safety signals seen
By Dermsquared Editorial Team | | September 28, 2022
Sentinel Lymph Node Biopsy Status Predicts Melanoma Survival
SLN positivity significantly associated with lower five-year disease-specific survival among patients with clinical stage IIB/C cutaneous melanoma
By Dermsquared Editorial Team | | September 28, 2022
Inflammatory Bowel Disease, Psoriasis May Be Causally Related
Genetic predisposition to psoriasis not linked to total IBD, but is associated with Crohn disease
By Physician's Briefing Staff | | September 22, 2022
Several Factors Significantly Tied to Atopic Dermatitis Disease Burden
Strongest associations seen for disease severity and time spent managing symptoms
By Physician’s Briefing Staff | | September 22, 2022
Roflumilast Yields Better Results for Chronic Plaque Psoriasis
Two multicenter trials show significantly greater percentage of patients treated with roflumilast versus vehicle had IGA success at week 8
By Dermsquared Editorial Team | | September 21, 2022
Burden of Ambulatory Hidradenitis Suppurativa Visits Up During Summer
51 percent of ambulatory visits for hidradenitis suppurativa occurred during May to August
By Dermsquared Editorial Team | | September 21, 2022
Psoriasis Patients Find Psoriatic Arthritis Screening Worthwhile
Participants report feeling empowered by comprehensive screening
By Physician’s Briefing Staff | | September 20, 2022
Dupilumab Eases Atopic Dermatitis in Children Younger Than 6 Years
Signs and symptoms of atopic dermatitis improved with dupilumab versus placebo in addition to topical corticosteroids
By Physician’s Briefing Staff | | September 19, 2022
Is Efficacy of Itraconazole for Tinea Corporis/Cruris Higher With Greater Dose?
400-mg dose of itraconazole achieves higher cure rate, but cost is 120 percent greater compared with 100-mg dose
By Dermsquared Editorial Team | | September 14, 2022
Few Europeans Use Photoprotection All Year Round
Only 56 percent of Europeans were aware that sun protection is useful when weather is overcast
By Dermsquared Editorial Team | | September 14, 2022
24 of 1200
Headline from the Week of February 09 - 15, 2026
Second Annual National Cancer Database Report Presented for 2022
By Elana Gotkine (HealthDay News) | | February 11, 2026
Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma
By Elana Gotkine (HealthDay News) | | February 11, 2026